我國就《疫苗管理法》公開向社會徵求意見
Vaccine producers could be given harsh penalties for a range of violations, with substantial fines possible, under a new draft law from China's top market regulator after a major quality control scandal earlier this year.
在今年早些時候發生重大疫苗質檢醜聞之後，中國最高市場管理部門近日公佈了一項新法律草案：疫苗生產商將因一系列違規行爲受到嚴厲懲罰，還可能面臨高額罰款。The State Administration for Market Regulation released the draft of a vaccine management law to solicit public opinions last Sunday.
上週日，國家市場監督管理總局發佈《疫苗管理法（徵求意見稿）》向公衆徵集意見。Serious violators could have profits confiscated, certificates revoked, production suspended and face fines of up to 10 times the value of the products in question.
嚴重違規者將被沒收利益所得、撤銷許可證、停產，最高將面臨問題產品貨值金額10倍的罰款。
Violations under scrutiny include falsifying manufacturing records and failing to recall products sold after quality issues or other potential safety risks were discovered, according to the draft.
根據該意見稿，須接受監督的違規行爲包括篡改生產記錄、對發現存在質量問題或其他潛在安全風險的產品未予以召回等。Senior executives and other employees at key posts within offending companies will have their salaries recalled during periods of infraction, and may be required to pay an additional fine of between 50-100% of their pay.
違規企業高管和關鍵崗位人員將被沒收其在違法期間自本單位所獲收入，並可能處以收入50%以上、一倍以下的罰款。They may be banned from engaging in pharmaceutical activities for life, according to the draft.
該意見稿稱，這些人還可能被終身禁止從事藥品相關活動。
